Is Toradol (ketorolac) appropriate for pain management in an 80‑year‑old female?

Toradol (Ketorolac) Should Be Avoided in an 80-Year-Old Female

Toradol is inappropriate for pain management in an 80-year-old patient and should be avoided. The 2019 American Geriatrics Society Beers Criteria explicitly lists ketorolac among NSAIDs to avoid in older adults due to high risk of serious adverse events 1. The FDA label mandates dose reduction for patients ≥65 years and emphasizes that elderly patients are at greater risk for serious gastrointestinal events and may clear the drug more slowly 2.

Why Ketorolac Is Particularly Dangerous in This Population

Guideline-Based Contraindications

The Beers Criteria designates all NSAIDs, including ketorolac, as potentially inappropriate medications in older adults with a strong recommendation based on high-quality evidence 1. The rationale centers on:

• Increased GI bleeding risk: Elderly patients face substantially higher rates of peptic ulcers, gastrointestinal bleeding, and perforation—events that can occur without warning 1, 2
• Cardiovascular thrombotic events: NSAIDs increase risk of MI and stroke, which may occur early in treatment 2
• Renal toxicity: Ketorolac is contraindicated in advanced renal impairment and high-risk patients. The elderly are more susceptible to acute renal failure, even with short-term use 2, 3

FDA Black Box Warnings Specific to the Elderly

The FDA label explicitly states that elderly patients require:

• Reduced dosages (lower than standard adult doses)
• Extreme caution and careful clinical monitoring
• Recognition that they are more sensitive to dose-related adverse effects 2

The label warns that risk increases dramatically with high doses, prolonged therapy (>5 days), or use in vulnerable patients—with the elderly specifically identified as a high-risk group 2, 4.

Critical Safety Concerns

Maximum Duration: 5 Days Only

Ketorolac is FDA-approved only for short-term use (up to 5 days maximum) for moderately severe acute pain requiring opioid-level analgesia 2. It is explicitly NOT indicated for chronic pain 2. The incidence of serious adverse events has declined since dosage guidelines were revised to limit duration and dose 4, 5.

Documented Adverse Events in the Elderly

• Acute renal failure: Case reports document reversible acute renal failure in elderly patients after just 3 doses of ketorolac 3
• GI complications: Risk of serious GI bleeding increases markedly with age, especially when used >5 days 5
• Bleeding complications: While controversial, ketorolac inhibits platelet function and is contraindicated in patients at high risk of bleeding 2

When Single-Dose Use Might Be Considered (With Extreme Caution)

The only scenario where ketorolac might be acceptable in a geriatric patient is a single parenteral dose in a carefully selected ED patient without contraindications. One 2020 study found that single doses of parenteral ketorolac in select geriatric ED patients (mean age 73) were not associated with increased adverse cardiovascular, GI, or renal outcomes compared to controls 6. However, this applies only to:

• Single dose administration (not repeated dosing)
• Carefully screened patients without risk factors
• Short-term acute pain in the ED setting

This does not apply to an 80-year-old patient requiring ongoing pain management.

Safer Alternatives for Geriatric Pain Management

For chronic pain in older adults, the 2020 JAGS guideline on adjuvant analgesics recommends 7:

• Topical analgesics for focal or regional pain (preferred when applicable)
• Duloxetine or secondary amine tricyclics (desipramine, nortriptyline) for multipurpose analgesia
• Gabapentinoids for neuropathic pain
• Acetaminophen as first-line for musculoskeletal pain (though not mentioned in provided evidence, this is standard geriatric practice)

All centrally acting agents must be initiated at low doses with gradual titration and careful monitoring in older adults 7.

Common Pitfalls to Avoid

• Never use ketorolac for chronic pain in any patient, especially the elderly 2
• Never exceed 5 days total duration (including IV/IM followed by oral) 2
• Never use standard adult doses in patients ≥65 years—dose reduction is mandatory 2
• Never prescribe without screening for: advanced age, renal impairment, volume depletion, heart failure, GI bleeding history, or concurrent anticoagulant/antiplatelet use 2, 3